Inovio Pharmaceuticals {NASDAQ: INO} has announced they have partnered with the National Cancer Institute and the Mayo Clinic to initiate a Hepatitis C immunotherapy trial.
DNA based immunotherapy will be tested for safety and immune responses.
The object is to eliminate Hepatitis C. Continue reading